Evidence map›Paper›PMID 30914715›Full record

ArticleScientific reports2019

Distinct mechanical properties in homologous spectrin-like repeats of utrophin.

Sivaraman Rajaganapathy, Jackie L McCourt, Sayan Ghosal, Angus Lindsay, Preston M McCourt, Dawn A Lowe, James M Ervasti, Murti V Salapaka

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Myotendinous Junction development and repair.Journal of orthopaedic translation · 2026
    Review
  2. Multiple modes of AFM reveal distinct mechanical properties for dystrophin and utrophin not manifest by small fragments.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024
    Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Sivaraman RajaganapathyDepartment of Electrical and Computer Engineering, University of Minnesota - Twin Cities, Minneapolis, MN, 55455, USA.
Jackie L McCourtDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota - Twin Cities, Minneapolis, MN, 55455, USA.
Sayan GhosalDepartment of Electrical and Computer Engineering, University of Minnesota - Twin Cities, Minneapolis, MN, 55455, USA.
Angus LindsayDepartment of Rehabilitation Medicine, University of Minnesota - Twin Cities, Minneapolis, MN, 55455, USA.
Preston M McCourtDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota - Twin Cities, Minneapolis, MN, 55455, USA.
Dawn A LoweDepartment of Rehabilitation Medicine, University of Minnesota - Twin Cities, Minneapolis, MN, 55455, USA.
James M ErvastiDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota - Twin Cities, Minneapolis, MN, 55455, USA. jervasti@umn.edu.
Murti V SalapakaDepartment of Electrical and Computer Engineering, University of Minnesota - Twin Cities, Minneapolis, MN, 55455, USA.
Twin Cities Orthopedics · USUniversity of Minnesota · US

Funding

TRAINING PROGRAM IN MUSCLE RESEARCHT32AR007612 · NIAMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI JAMES M ERVASTI, DAWN A LOWE · 2001 to 2026
$11.3M
CYTOSKELETAL INTERACTIONS OF DYSTROPHINR01AR042423 · NIAMS · UNIVERSITY OF WISCONSIN MADISON · PI ERVASTI, JAMES M · 1994 to 2025
$9.3M
NIAMS NIH HHS R01 AR042423NIAMS NIH HHS T32 AR007612
6 · The paper itself

Abstract

Patients with Duchenne muscular dystrophy (DMD) lack the protein dystrophin, which is a critical molecular component of the dystrophin-glycoprotein complex (DGC). Dystrophin is hypothesized to function as a molecular shock absorber that mechanically stabilizes the sarcolemma of striated muscle through interaction with the cortical actin cytoskeleton via its N-terminal half and with the transmembrane protein β-dystroglycan via its C-terminal region. Utrophin is a fetal homologue of dystrophin that can subserve many dystrophin functions and is therefore under active investigation as a dystrophin replacement therapy for DMD. Here, we report the first mechanical characterization of utrophin using atomic force microscopy (AFM). Our data indicate that the mechanical properties of spectrin-like repeats in utrophin are more in line with the PEVK and Ig-like repeats of titin rather than those reported for repeats in spectrin or dystrophin. Moreover, we measured markedly different unfolding characteristics for spectrin repeats within the N-terminal actin-binding half of utrophin compared to those in the C-terminal dystroglycan-binding half, even though they exhibit identical thermal denaturation profiles. Our results demonstrate dramatic differences in the mechanical properties of structurally homologous utrophin constructs and suggest that utrophin may function as a stiff elastic element in series with titin at the myotendinous junction.

Indexed as

AnimalsMiceMicroscopy, Atomic ForceProtein DomainsRepetitive Sequences, Amino AcidSpectrinUtrophinSpectrinUtrophin

Identifiers

PMID30914715
PMCPMC6435810
OpenAlexW2924782702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.